Invasive Aspergillosis Complicating Severe COVID-19: Cumulative Incidence, Risk Factors, and Outcomes Between the First Wave of the Pandemic and Subsequent Waves, According to the ECMM/ISHAM Classification and a Local Case Assessment.

Publication date: Sep 01, 2026

The role of severe COVID-19 as an independent risk factor for invasive aspergillosis remains debated, with reported incidences varying widely across studies. We compared the cumulative incidence, risk factors, and outcomes of invasive pulmonary mold infection (IPMI) in intensive care unit patients with confirmed COVID-19 during the first epidemic wave and subsequent waves up to March 2021 at La PiticE9-SalpcEAtricE8re Hospital, Paris, France. Patients were systematically screened for fungal infections and classified according to ECMM/ISHAM criteria and a more stringent local assessment. The study included 259 patients (n = 171, first wave and n = 88, subsequent waves). Patient characteristics were similar between periods, although short-course corticosteroid therapy increased over time. Mortality rates remained unchanged. Cumulative incidence of IPMI did not differ significantly between waves, regardless of the classification system used: 12. 1% versus 15. 1% with ECMM/ISHAM criteria and 4. 2% versus 5. 8% with local assessment. IPMI was associated with solid organ transplantation and pre-existing long-term corticosteroid therapy, whereas short-course corticosteroid therapy for COVID-19 was not associated with increased risk. IPMI was strongly associated with 90-day mortality. Classification as probable COVID-19-Associated Pulmonary Aspergillosis using the ECMM/ISHAM criteria may be partly influenced by the number of diagnostic samples collected. Overall, our findings underline that the classification system substantially influences both incidence estimates and the interpretation of survival outcomes.

Open Access PDF

Concepts Keywords
Aspergillosis Aspergillus
Fungi CAPA
March classification criteria
Paris colonization
Therapy corticosteroids
molds
SARS-CoV-2

Semantics

Type Source Name
disease MESH Aspergillosis
disease MESH COVID-19
disease MESH infection
disease MESH fungal infections
disease MESH included
disease MESH Pulmonary Aspergillosis
drug DRUGBANK Diethylstilbestrol
disease MESH des
disease MESH Inflammation
disease MESH CAPA
disease MESH invasive pulmonary aspergillosis
drug DRUGBANK Riboprine
disease MESH IPA
disease MESH superinfection
disease MESH pneumonia
disease MESH influenza
disease MESH lymphopenia
disease MESH viral infections
drug DRUGBANK Coenzyme M
disease MESH bed
disease MESH acute respiratory distress syndrome
disease MESH clinical progression
disease MESH pulmonary fusariosis
drug DRUGBANK Dimercaprol
drug DRUGBANK Silver
disease MESH Ger
drug DRUGBANK Chloramphenicol
drug DRUGBANK Gentamicin
drug DRUGBANK Trestolone
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Lopinavir
disease MESH invasive fungal infection
disease MESH Hypertension
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH Hematological malignancy

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *